Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTOVXHF)

• DTT Name: Human Deoxyribonucleic acid minor groove (hDNA min)
• Gene Name: hDNA min
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T71536

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lurbinectedin	DMEFRTZ	Small-cell lung cancer	2C25.Y	Approved	[2]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brostallicin	DMUI5PA	Breast cancer	2C60-2C65	Phase 2	[1]

4 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Di-imidazole lexitropsin	DME4NH1	Discovery agent	N.A.	Investigative	[3]
Distamycin A	DMPVNDK	Discovery agent	N.A.	Investigative	[4]
Duocarmycin	DM0CQIP	Discovery agent	N.A.	Investigative	[5]
Netropsin	DMOW2QS	Discovery agent	N.A.	Investigative	[6]

References

• [1] Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [3] Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure. 1997 Aug 15;5(8):1033-46.
• [4] Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14.
• [5] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [6] Drug-DNA binding specificity: binding of netropsin and distamycin to poly(d2NH2A-dT). Biopolymers. 1990;30(1-2):223-7.